SK Biopharmaceuticals Licenses Biohaven’s Kv7 Platform in Deal Worth Up to $795 Million
SK Biopharm gains exclusive worldwide rights to Biohaven’s opakalim and Kv7 platform in a deal worth up to $795M, with a possible 2029 U.S. launch.
/ 4 items
#XENE↓
BofA Downgrades Biohaven to Underperform, Cuts Price Target to $11 on Kv7 Risks
Analyst highlights competition risk in Kv7 epilepsy program and cuts peak sales forecast.
Xenon’s Azetukalner Shows Record Efficacy in Phase 3 Epilepsy Trial
Xenon Pharmaceuticals reported strong Phase 3 results for azetukalner in focal onset seizures. The drug reduced monthly seizures by 53.2% vs 10.4% on placebo. NDA filing planned for Q3 2026.
Biohaven's Depression Drug BHV-7000 Falls Short in Clinical Trial
Biohaven's (BHVN) experimental depression treatment BHV-7000 didn't meet its primary goal in Phase 2 testing, though some patient subgroups showed promising trends.